## PATENT FORAMEN OVALE (PFO) CLOSURE — ECONOMIC VALUE

"Cost-effectiveness of percutaneous closure of a patent foramen ovale (PFO) compared with medical management in patients with a cryptogenic stroke: from the U.S. payer perspective" adapted from *Journal of Medical Economics* 

## Cost effectiveness

After 2.3 years, closing a PFO with GORE<sup>®</sup> CARDIOFORM Septal Occluder is cost-effective compared to medical management alone.<sup>1</sup>

## Quality of life

PFO closure plus medical management improves quality of life compared to medical management alone.<sup>1</sup>

Average quality adjusted life years (QALYs) treatment comparison relative to perfect health in a 5 year span



QALYs is commonly used in health economics to quantify the effectiveness of a particular intervention. QALYs combines the impact of gains in quality of life and in quantity of life associated with an intervention. One QALY is equal to 1 year of life in perfect health.<sup>\*,2</sup>

What does the difference in average QALYs between the two treatments mean for the patient?

Within a 5 year span patients treated with PFO closure plus medical management experienced five more months of improved health related quality of life relative to patients treated with medical management alone.<sup>1</sup>



- \* Measured in terms of the person's ability to carry out the activities of daily life, and freedom from pain and mental disturbance.
- 1. Volpi JJ, Ridge JR, Nakum M, Rhodes JF, Sondergaard L, Kasner SE. Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective. *Journal of Medical Economics* 2019;22(9):883-890.
- 2. NICE glossary. National Institute for Health and Care Excellence (NICE) Web site. https://www.nice.org.uk/glossary. Accessed August 29, 2019.

**INDICATIONS FOR USE IN AUSTRALIA, CANADA AND EUROPE:** The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of atrial septal defects (ASDs), such as ostium secundum and patent foramen ovale. **CONTRAINDICATIONS:** The GORE® CARDIOFORM Septal Occluder is contraindicated for use in patients: unable to take anti-platelet or anticoagulant medications such as aspirin, heparin or warfarin; with anatomy where the GORE® CARDIOFORM Septal Occluder size or position would interfere with other intracardiac or intravascular structures, such as cardiac valves or pulmonary veins; with active endocarditis, or other infections producing bacteremia, or patients with known intracardiac thrombi. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and contraindications. <sup>R</sup>ow

**INDICATIONS FOR USE IN THE U.S.:** The GORE® CARDIOFORM Septal Occluder is a permanently implanted device indicated for the percutaneous, transcatheter closure of ostium secundum atrial septal defects (ASDs). **CONTRAINDICATIONS:** The GORE® CARDIOFORM Septal Occluder is contraindicated for use in patients: Unable to take anti-platelet or anticoagulant medications such as aspirin, heparin or warfarin; with anatomy where the GORE® CARDIOFORM Septal Occluder size or position would interfere with other intracardiac or intravascular structures, such as cardiac valves or pulmonary veins; with active endocarditis, or other infections producing bacteremia, or patients with known intracardiac thrombi. Refer to *Instructions for Use* at goremedical.com for a complete description of all warnings, precautions and contraindications. Romy

Products listed may not be available in all markets.

GORE, *Together, improving life,* CARDIOFORM and designs are trademarks of W. L. Gore & Associates, Inc. © 2019 W. L. Gore & Associates, Inc. NOVEMBER 2019

